A patient who develops a lowered eyelid, altered smile or swallowing difficulty after treatment does not need reassurance alone. They need a clinician who can distinguish a predictable pharmacological effect from a developing medical concern, document the facts clearly and act within an appropriate escalation pathway. Botulinum toxin complication management is therefore not a single rescue technique. It is a disciplined clinical process extending from prevention and assessment to communication, follow-up and, where necessary, urgent referral.
For aesthetic practitioners, complications management is also a measure of professional maturity. Excellent outcomes depend on anatomical precision and sound product knowledge; safe practice depends equally on recognising when the outcome is no longer following the expected course.
The first task: identify what has happened
Most unwanted outcomes after botulinum toxin are local, temporary and related to dose, placement, diffusion, patient anatomy or baseline asymmetry. Their timing matters. Aesthetic effect usually begins within several days and reaches its maximum at around two weeks. An adverse outcome that appears in this period may be treatment-related, but temporal association is not, by itself, proof of causation.
A structured assessment should establish the product used, batch number, dilution, dose at each site, injection depth, needle placement, treatment date and any previous exposure. Baseline photographs and a record of pre-existing asymmetry are clinically valuable, particularly in the upper face and perioral region. Ask about concurrent illness, new medicines, neuromuscular history, ocular disease and whether another practitioner has treated the same area.
Examination should be purposeful. Assess facial movement at rest and animation, eyelid position, brow position, ocular motility, speech, smile, oral competence and swallowing where relevant. Document the patient’s account in their own words as well as objective findings. This protects continuity of care and prevents a complication being managed from memory or assumption.
Botulinum toxin complication management begins with triage
The key question is whether the presentation is local and self-limiting, functionally significant but non-emergent, or potentially systemic. The vast majority of aesthetic complications fall into the first two categories. The rare but serious exceptions demand immediate action.
Symptoms such as progressive dysphagia, dysarthria, dyspnoea, generalised weakness, impaired cough, visual disturbance associated with neurological signs, or symptoms suggesting anaphylaxis require urgent medical assessment. Do not attempt to manage these presentations remotely, minimise them because the injected dose was modest, or wait for a routine review. Escalation through emergency services or acute medical care should be proportionate to the symptoms, with clear handover of the toxin product, dose, timing and clinical findings.
This distinction is particularly relevant because botulinum toxin has no routine aesthetic ‘reversal’ agent. Unlike some injectable complications, management often centres on accurate diagnosis, supportive measures, time, functional protection and specialist referral. That reality makes prevention and early recognition essential.
Managing common local complications
Eyelid ptosis and brow ptosis
Upper-face complications are among the most recognisable. True eyelid ptosis reflects weakness affecting the levator mechanism, whereas brow ptosis follows excessive weakening of the frontalis or treatment that disrupts the balance between brow depressors and elevators. The difference is not academic: the examination, explanation and management plan will differ.
For mild cases, explain the expected temporary course, assess visual function and arrange review. In selected patients, a suitably qualified prescriber may consider prescription ophthalmic treatment intended to elevate the upper lid temporarily. This requires appropriate assessment, awareness of contraindications and clear counselling. It is not a substitute for examining the patient or excluding ocular pathology.
Brow ptosis is usually managed conservatively. Further toxin in an attempt to ‘correct’ the problem can worsen the loss of frontalis support. A considered approach may occasionally involve limited treatment of untreated depressor activity, but only after reassessment of the original pattern, existing movement and the patient’s functional needs. When in doubt, avoid reactive injection and seek experienced input.
Asymmetry, altered smile and lower-face weakness
Subtle asymmetry is common even before treatment. It becomes clinically relevant when treatment magnifies it or creates visible imbalance during animation. In the lower face, diffusion or excessive dosing may affect smile elevation, lip competence, speech articulation or drinking from a cup. These outcomes can be distressing despite being temporary, particularly for patients whose work involves public speaking or performance.
Management starts with frank acknowledgement. Review baseline images, map dynamic movement and establish whether the issue is improving, stable or progressing. Small balancing adjustments may be appropriate in carefully selected cases, but they carry a trade-off: the attempt to create symmetry can reduce movement further or extend the duration of functional change. Conservative observation is often the safer course when weakness is already prominent.
Diplopia, dry eye and ocular symptoms
Diplopia following periocular treatment requires careful assessment and should not be dismissed as a cosmetic nuisance. New double vision, particularly if persistent, warrants ophthalmic or urgent medical review depending on severity and associated symptoms. Dry eye, incomplete blink or discomfort may occur where orbicularis function has been affected. Protecting the ocular surface and involving an eye-care specialist when symptoms are significant is preferable to assuming the issue will simply resolve.
Dysphagia and neck weakness
Neck treatment requires particular caution because treatment effects can interfere with head support and swallowing. A patient who reports mild fatigue or local weakness may be monitored closely if clinically stable. Difficulty swallowing liquids, coughing during meals, a weak voice, weight loss, dehydration risk or respiratory symptoms should lower the threshold for urgent assessment. The patient’s baseline health, frailty, neurological history and the muscles treated all influence the appropriate response.
Communication is part of treatment
Patients judge a complication not only by its duration, but by the quality of the response they receive. A defensive explanation or delayed reply can turn a temporary pharmacological effect into a profound loss of trust. The appropriate tone is calm, factual and compassionate: acknowledge the concern, explain what is known and unknown, set out the safety plan, and give a realistic timeframe without making guarantees.
Avoid telling a patient that a result is ‘normal’ before assessing whether it is normal for them. Equally, avoid language that overstates permanence or implies blame. A well-managed consultation should leave the patient knowing who to contact, what symptoms require urgent attention, when review will occur and what interventions are being considered.
For Professor Patrick Treacy, patient safety in aesthetic medicine is inseparable from education and clinical accountability. The clinician’s responsibility does not end when the injection is complete; it continues through accessible aftercare and appropriately documented follow-up.
Prevention is the strongest intervention
Good botulinum toxin complication management starts before the consent form is signed. Patient selection should account for facial anatomy, muscle strength, prior responses, eyelid and brow position, dry-eye symptoms, neuromuscular conditions, medicines that may affect neuromuscular transmission, and realistic expectations. A technically correct pattern on a generic facial map may still be inappropriate for an individual patient.
Conservative dosing is not a lack of confidence. It is often the more sophisticated choice, especially for first treatments, lower-face indications, patients with heavy brows, those with a short forehead, or individuals seeking preserved expression. A two-stage plan can be safer than pursuing a maximal result in one appointment.
The clinic should also have a written complications protocol. It should specify how patients access urgent advice, which symptoms trigger same-day review or referral, how clinical photography and records are stored, and who is responsible for follow-up. Staff must know the protocol well enough to recognise a potential red flag rather than merely book the next available appointment.
When referral is the right clinical decision
Referral is not an admission of failure. It is good medicine when symptoms exceed the clinician’s scope, when diagnosis is uncertain, or when specialist assessment could protect function. Ophthalmology, neurology, emergency medicine, speech and language therapy, and primary care may all have a role depending on the presentation.
The referring clinician should provide a concise, factual account: indication, product, total dose, anatomical sites, date of treatment, onset and progression of symptoms, relevant medical history and findings on examination. This reduces delay and demonstrates the standard of care expected in a medically led aesthetic practice.
Patients remember whether their practitioner remained present, precise and honest when the outcome was not as intended. That is why the most valuable complication protocol is not merely a document in a clinic folder, but a culture of careful assessment, early escalation and respect for the person behind every treatment.